Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis.

  title={Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis.},
  author={J. Langston and P. Ballard and J. Tetrud and I. Irwin},
  volume={219 4587},
Four persons developed marked parkinsonism after using an illicit drug intravenously. Analysis of the substance injected by two of these patients revealed primarily 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP) with trace amounts of 1-methyl-4-phenyl-4-propionoxy-piperidine (MPPP). On the basis of the striking parkinsonian features observed in our patients, and additional pathological data from one previously reported case, it is proposed that this chemical selectively damages cells in… Expand

Paper Mentions

MPTP-Induced Parkinsonian Syndromes in Humans and Animals
The history of this discovery, the present knowledge of MPTP- induced motor disorders, and the implications for understanding spontaneously occurring Parkinson’s Disease are recounted. Expand
Permanent human parkinsonism due to 1‐methy 1–4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP)
Neither prolonged levodopa treatment nor progressive disease was necessary for on-off phenomena, because the neurotoxic effects of MPTP seem limited to the substantia nigra, and damage to this system alone may produce all the motor features of Parkinson's disease. Expand
MPTP-induced parkinsonism in monkeys: mechanism of action, selectivity and pathophysiology.
The symptoms largely replicated those of idiopathic parkinsonism, and further parallelisms included the destruction of nigrostriatal dopamine neurons, changes of biogenic amine metabolites in cerebrospinal fluid, response to DA precursor or agonist drug therapy, on-off phenomena and druginduced dyskinesia. Expand
Experimental parkinsonian syndrome induced in rats by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
An essential condition for the development of effective treatment of parkinsonism is the creation of a pathogenetically adequate model of this highly complex syndrome. It has recently been shown thatExpand
Pattern of dopaminergic loss in the striatum of humans with parkinsonism induced by MPTP.
It transpired that the chemist who had made the offending drug had unwittingly synthesised 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), which proved to be a potent and specific nigral toxin. Expand
Pattern of dopaminergic loss in the striatum of humans with parkinsonism induced by MPTP
  • G. Sawle
  • Medicine
  • Journal of neurology, neurosurgery, and psychiatry
  • 2000
A sheep model for MPTP induced Parkinson-like symptoms.
A sheep model which responds to administration of low levels of the compound with well defined, apparently permanent symptomology very similar to that seen in primates is reported. Expand
Detection of Tetrahydroisoquinoline, a Parkinsonism-Related Compound, in Parkinsonian Brains and Foods by Gas Chromatography-Mass Spectrometry
After 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) was discovered to cause parkinsonism in humans, monkeys, and mice,1–2 Nagatsu et al. screened various compounds structurally similar to MPTPExpand
Clinical and biochemical parameters of parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and its methyl-phenyl and methoxy-phenyl derivatives in C57B1/6 mice
Only Ortho-methylphenyl- and ortho-methoxyphenyl-derivates of MPTP cause a persistent loss in dopamine content in the brain and produced the clinical symptoms of parkinsonism. Expand
An endogenous substance of the brain, tetrahydroisoquinoline, produces parkinsonism in primates with decreased dopamine, tyrosine hydroxylase and biopterin in the nigrostriatal regions
The results suggest that TIQ is one of the candidates of neurotoxins to produce parkinsonism. Expand


Chronic parkinsonism secondary to intravenous injection of meperidine analogues
Biogenic amines and metabolites in the cerebrospinal fluid and microscopic evaluation of the brain at necropsy were consistent with damage to aminergic neurons in the substantia nigra. Expand
Apraxia of lid opening is a nonparalytic motor abnormality characterized by the patient's difficulty in initiating the act of lid elevation. It differs from paralytic ptosis by being present onlyExpand
Piperidine derivatives; 4-arylpiperidines.